BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

208 related articles for article (PubMed ID: 15563182)

  • 21. A phosphorylated prodrug for the inhibition of Pin1.
    Zhao S; Etzkorn FA
    Bioorg Med Chem Lett; 2007 Dec; 17(23):6615-8. PubMed ID: 17935986
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modulating the Affinities of Phosphopeptides for the Human Pin1 WW Domain Using 4-Substituted Proline Derivatives.
    Huang KY; Horng JC
    Biochemistry; 2015 Oct; 54(40):6186-94. PubMed ID: 26406962
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Pin1: a multi-talented peptidyl prolyl cis-trans isomerase and a promising therapeutic target for human cancers].
    Marsolier J; Weitzman JB
    Med Sci (Paris); 2014; 30(8-9):772-8. PubMed ID: 25174754
    [TBL] [Abstract][Full Text] [Related]  

  • 24. An essential role for Pin1 in Xenopus laevis embryonic development revealed by specific inhibitors.
    Wildemann D; Hernandez Alvarez B; Stoller G; Zhou XZ; Lu KP; Erdmann F; Ferrari D; Fischer G
    Biol Chem; 2007 Oct; 388(10):1103-11. PubMed ID: 17937625
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Unexpected roles of the peptidyl-prolyl cis/trans isomerase Pin1].
    Lavoie SB; Albert AL; Vincent M
    Med Sci (Paris); 2003 Dec; 19(12):1251-8. PubMed ID: 14691750
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dual Roles of Pin1 in Cancer Development and Progression.
    Han HJ; Choi BY; Surh YJ
    Curr Pharm Des; 2017 Nov; 23(29):4422-4425. PubMed ID: 28671058
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Discovery and characterization of a nonphosphorylated cyclic peptide inhibitor of the peptidylprolyl isomerase, Pin1.
    Duncan KE; Dempsey BR; Killip LE; Adams J; Bailey ML; Lajoie GA; Litchfield DW; Brandl CJ; Shaw GS; Shilton BH
    J Med Chem; 2011 Jun; 54(11):3854-65. PubMed ID: 21545152
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Structure-guided design of alpha-amino acid-derived Pin1 inhibitors.
    Potter AJ; Ray S; Gueritz L; Nunns CL; Bryant CJ; Scrace SF; Matassova N; Baker L; Dokurno P; Robinson DA; Surgenor AE; Davis B; Murray JB; Richardson CM; Moore JD
    Bioorg Med Chem Lett; 2010 Jan; 20(2):586-90. PubMed ID: 19969456
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inhibition of peptidyl-prolyl cis/trans isomerase activity by substrate analog structures: thioxo tetrapeptide-4-nitroanilides.
    Schutkowski M; Wöllner S; Fischer G
    Biochemistry; 1995 Oct; 34(40):13016-26. PubMed ID: 7548060
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mechanistic insights into Pin1 peptidyl-prolyl cis-trans isomerization from umbrella sampling simulations.
    Di Martino GP; Masetti M; Cavalli A; Recanatini M
    Proteins; 2014 Nov; 82(11):2943-56. PubMed ID: 25066180
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cyclohexyl ketone inhibitors of Pin1 dock in a trans-diaxial cyclohexane conformation.
    Xu GG; Slebodnick C; Etzkorn FA
    PLoS One; 2012; 7(9):e44226. PubMed ID: 23028504
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nanomolar inhibitors of the peptidyl prolyl cis/trans isomerase Pin1 from combinatorial peptide libraries.
    Wildemann D; Erdmann F; Alvarez BH; Stoller G; Zhou XZ; Fanghänel J; Schutkowski M; Lu KP; Fischer G
    J Med Chem; 2006 Apr; 49(7):2147-50. PubMed ID: 16570909
    [TBL] [Abstract][Full Text] [Related]  

  • 33. A Selective, Cell-Permeable Nonphosphorylated Bicyclic Peptidyl Inhibitor against Peptidyl-Prolyl Isomerase Pin1.
    Jiang B; Pei D
    J Med Chem; 2015 Aug; 58(15):6306-12. PubMed ID: 26196061
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prevalent overexpression of prolyl isomerase Pin1 in human cancers.
    Bao L; Kimzey A; Sauter G; Sowadski JM; Lu KP; Wang DG
    Am J Pathol; 2004 May; 164(5):1727-37. PubMed ID: 15111319
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The peptidyl prolyl cis/trans-isomerase Pin1 recognizes the phospho-Thr212-Pro213 site on Tau.
    Smet C; Sambo AV; Wieruszeski JM; Leroy A; Landrieu I; Buée L; Lippens G
    Biochemistry; 2004 Feb; 43(7):2032-40. PubMed ID: 14967043
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Peptidyl-prolyl isomerase inhibitors.
    Wang XJ; Etzkorn FA
    Biopolymers; 2006; 84(2):125-46. PubMed ID: 16302169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Phosphorylation-specific prolyl isomerization: is there an underlying theme?
    Wulf G; Finn G; Suizu F; Lu KP
    Nat Cell Biol; 2005 May; 7(5):435-41. PubMed ID: 15867923
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Regulation of Pin1 peptidyl-prolyl cis/trans isomerase activity by its WW binding module on a multi-phosphorylated peptide of Tau protein.
    Smet C; Wieruszeski JM; Buée L; Landrieu I; Lippens G
    FEBS Lett; 2005 Aug; 579(19):4159-64. PubMed ID: 16024016
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Recent advances of Pin1 inhibitors as potential anticancer agents.
    Bai Y; Yuan Z; Yuan S; He Z
    Bioorg Chem; 2024 Mar; 144():107171. PubMed ID: 38325131
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pin1 acts catalytically to promote a conformational change in Cdc25.
    Stukenberg PT; Kirschner MW
    Mol Cell; 2001 May; 7(5):1071-83. PubMed ID: 11389853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.